论文部分内容阅读
目的:研究扶正化瘀胶囊联合复方牛胎肝提取物片治疗肝硬化的临床疗效。方法:选取本院接诊的74例肝硬化患者为研究对象,随机分为对照组和观察组,各37例。对照组采用复方牛胎肝提取物片治疗,观察组则采用扶正化瘀胶囊联合复方牛胎肝提取物片治疗。比较2组患者治疗前后的肝功能[谷丙转氨酶(ALT)、谷草转氨酶(AST)及总胆红素(TBil)]及肝纤维化[透明质酸(HA)、层黏蛋白(LN)及三型前胶原(PC-Ⅲ)]指标,并评定疗效。结果:对照组总有效率为78.38%,观察组为97.30%,2组比较,差异有统计学意义(P<0.05)。治疗前2组患者ALT、AST及TBil水平比较,差异均无统计学意义(P>0.05)。治疗后,2组患者ALT、AST及TBil水平均明显降低;且治疗后,观察组患者的ALT、AST及TBil水平均明显低于对照组,差异有统计学意义(P<0.05)。治疗前,2组患者的HA、LN及PC-Ⅲ等指标的比较,差异均无统计学意义(P>0.05)。治疗后,2组患者的HA、LN及PC-Ⅲ等指标的水平均明显降低;且治疗后,观察组患者的HA、LN及PC-Ⅲ的水平均明显低于对照组,差异有统计学意义(P<0.05)。结论:扶正化瘀胶囊联合复方牛胎肝提取物片治疗肝硬化,临床疗效良好,值得临床推广应用。
Objective: To study the clinical efficacy of Fuzheng Huayu capsule combined with compound cocofetal liver extract in the treatment of liver cirrhosis. Methods: Seventy-four patients with cirrhosis admitted to our hospital were selected as study subjects and randomly divided into control group and observation group, with 37 cases in each group. The control group was treated with compound bovine fetal liver extract tablets, and the observation group was treated with Fuzhenghuayu capsule combined with compound bovine fetal liver extract tablets. The liver function (ALT, AST and TBil) and hepatic fibrosis (HA, LN) before and after treatment were compared between the two groups. Three types of procollagen (PC-Ⅲ)] indicators, and assess the efficacy. Results: The total effective rate was 78.38% in the control group and 97.30% in the observation group. There was significant difference between the two groups (P <0.05). There was no significant difference in the levels of ALT, AST and TBil between the two groups before treatment (P> 0.05). After treatment, the levels of ALT, AST and TBil were significantly decreased in both groups. After treatment, the levels of ALT, AST and TBil in the observation group were significantly lower than those in the control group (P <0.05). Before treatment, there was no significant difference in HA, LN and PC-Ⅲ among the two groups (P> 0.05). After treatment, the levels of HA, LN and PC-Ⅲ were significantly decreased in both groups. After treatment, the levels of HA, LN and PC-Ⅲ in the observation group were significantly lower than those in the control group Significance (P <0.05). Conclusion: Fuzhenghuayu capsule combined with compound bovine fetal liver extract tablets for the treatment of liver cirrhosis, clinical efficacy is good, it is worthy of clinical promotion and application.